Acute graft-versus-host disease (GVHD) is most often treated with high dose glucocorticoids, but less than half of patients have durable overall improvement. Previous phase I and phase I1 studies suggested that treatment with a CD5-specific immunotoxin (XomaZyme-CD5 Plus) could ameliorate symptoms of GVHD. In a randomized, double-blind trial, we compared XomaZyme-CD5 Plus and glucocorticoids versus placebo and glucocorticoids as initial therapy for 243 patients who developed acute GVHD after allogeneic marrow transplantation. The study drug (XomaZyme CD5-Plus or an identical appearing placebo) was administered at a dose of 0.1 mglkg body weight on each of 14 consecutive days. All patients were treated concomitantly with a standard regimen of methylprednisolone. At the time of entry on study, 94% of patients had a rash, 56% had hyperbilirubinemia, 61% had diarrhea, and 84% had nausea and vomiting. At 3,4, and 5 weeks after starting treatment, symptom severity was less in the CD5 group than in the placebo group.
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CUTE GRAFT-VERSUS-HOST disease (GVHD) re-
A mains a major cause of morbidity and mortality after allogeneic marrow transplantation.' This complication is initiated by donor T cells, which are activated by host alloantigens.' Patients with GVHD are at high risk of developing infections because lesions in the skin and gastrointestinal tract disrupt physical barriers that would otherwise impede entry of organisms and because immune function already impaired by virtue of the transplant is further compromised by GVHD. The dilemma in treating GVHD is how to provide sufficient immunosuppression for control of the disease without increasing susceptibility to infections. Currently, acute GVHD is most often treated with high dose glucocorticoids that have potent anti-inflammatory effects, but less than half of patients have durable overall impr~vement.~.' ' Many patients require secondary treatment,'* and many die from GVHD itself or from infections.
XomaZyme-CD5 Plus is an immunotoxin composed of ricin-A chain linked by a disulfide bond to a murine IgGl monoclonal antibody (MoAb) specific for CD5, a cell surface molecule expressed on human T lymphocyte^.'^ Previous phase I and phase I1 studies have evaluated the use of CD5-close monitoring and appropriate adjustment of treatment. The combined administration of a CD5-specific immunotoxin and glucocorticoids controls GVHD manifestations more effectively than treatment with glucocorticoids alone during the first 5 weeks after starting treatment. Use of this immunotoxin does not result in any long-term clinical benefii for patients with acute GVHD.
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Plus for treatment of steroid-refractory acute GVHD after allogeneic marrow tran~plantation.'~.'' The clinical responses observed in some patients suggested that the immunotoxin might have an immunosuppressive effect that could complement the predominantly anti-inflammatory effects of glucocorticoids. We now report the results of a double-blind trial comparing CD5-Plus and glucocorticoids versus placebo and glucocorticoids as initial therapy for patients with acute GVHD.
MATERIALS AND METHODS
Patients were eligible to participate in this study when they developed acute GVHD manifested by (1) a characteristic rash involving over 50% of the body surface; (2) rash of any extent together with visceral involvement as indicated by increasing serum bilirubin >2.0 mg/dL, persistent nausea and vomiting, or diarrhea >500 mWd (>30 mUkg in children); or by (3) visceral involvement in the absence of rash but confirmed by biopsy. Patients were excluded if they had received T-cell-depleted marrow or more than one marrow transplant or had any prior treatment for acute GVHD.
Also excluded were patients who had acute life-threatening illness other than GVHD. Randomization was carried out after obtaining written informed consent using forms approved by the Institutional Review Board. Assignment to one of the two treatment arms was made by computerized biased coin adaptive rand~mization'~," in order to ensure that the two treatment arms were balanced with respect to risk factors known or suspected to influence the response to treatment.'" Treatment. All patients were administered methylprednisolone at a dose of 1.0 mgkg twice daily for 18 days. When tolerated, oral prednisone was substituted for intravenous methylprednisolone with appropriate adjustment in the dose. Beginning on the 19th day, the dose of prednisone was decreased by 0.2 mgkg body weight every 5 days in patients who had no clinical evidence of active GVHD. No tapering of glucocorticoid doses was allowed until symptoms of acute GVHD had resolved. The taper schedule was suspended whenever symptoms of acute GVHD recurred and was resumed when symptoms resolved.
The study drug (XomaZyme CDS-Plus or an identical appearing
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For personal use only. on October 27, 2017. by guest www.bloodjournal.org From CD5-SPECIFIC IMMUNOTOXIN FOR GVHD 825 placebo) was supplied by Xoma Corp (Berkley, CA) and was administered daily as a 1 hour intravenous infusion at a dose of 0.1 mgl kg body weight. Administration of the study drug was continued for a total of 14 doses regardless of clinical response or secondary therapy; it was suspended per protocol whenever there was evidence that it might be causing moderate or severe organ toxicity, hypoalbuminemia, or renal impairment. Resumption of treatment with the study drug was allowed if toxicity improved within 3 days. Otherwise, it was discontinued.
Medications originally administered for GVHD prophylaxis were continued throughout treatment of GVHD unless there was toxicity or contraindication. When renal toxicity occurred, priority was given to continuing the administration of cyclosporine prophylaxis rather than the study drug. Protocol guidelines for starting secondary treatment of acute GVHD included (1) worsening of symptoms for at least 3 days; (2) unimproving grades 111-IV GVHD persisting for at least 1 week despite treatment; or (3) unimproving grade I1 GVHD persisting for at least 2 weeks despite treatment (see ref 18 for grading of GVHD).
Symptom severity. Measurements of rash, serum bilirubin, average daily stool volume (3 day measurements for inpatients with diarrhea), and serum creatinine were recorded weekly through week 6 after starting treatment for GVHD and at the time of departure from Seattle. Additional weekly notations recorded the presence of visible blood in the stool or symptoms of nausea, vomiting, or abdominal cramping. All abnormalities were recorded whether caused by GVHD or by other complications.
Grading of clinical symptom severity was patterned after the system described by Glucksberg et al.'* For all organs, stage 0 indicates normal function. Skin severity was categorized according to the extent of rash and presence of bullae: stage 1, 525% of the skin surface area; stage 2, 26% to 50%; stage 3, >50%; stage 4, bulla formation. Liver severity was categorized according to the serum total bilirubin concentration: stage 1, 2 to 2.9 mgldL; stage 2, 3 to 5.9 mg/dL; stage 3, 6 to 14.9 mg/dL; stage 4, 215 mgldL. Gut severity was categorized according to a scoring system for symptoms of diarrhea, cramps, and visible blood in the stool. Symptoms were evaluated on the day of enrollment (day 1) and the 2 preceeding days, and on days 6-8, 13-15,20-22,27-29,34-36, and 41-43. Scores of 1, 2, and 3 were assigned, respectively, for diarrhea with average daily volumes <l,OOO mL, 1,000-1.499 mL, and 21,500 (<556 mUmz body surface, 556-833 a m z , and >833 a m z in children with body surface area < 1.0 m'). A score of 2 was assigned when abdominal cramps were present and also when visible blood was present in the stool. Overall stage 1 gut severity was assigned for a total symptom score of 1 and for patients whose symptoms were limited to nausea and vomiting. Overall stages 2, 3, and 4 were assigned, respectively, for total gut symptom scores of 2, 3-4, and 5-7. Diarrhea volumes containing admixed urine were not included in calculating the 3-day average. If urinary mixing was present on all 3 days, a score of 1 was assigned when the average daily volume was <1,OOO mL (t556 mUm2 in children), and no evaluation of gut severity could be made when the average daily volume was >1,OOO mL (>556 mL/mz in children).
Grade I overall symptom severity was defined as stage 1-2 skin severity with stage 0 liver and gut seventy. Grade 11 overall symptom severity was defined as stage 3 skin severity or stage 1 liver or gut severity. Grade 111 overall symptom severity was defined as stage 2-3 liver or gut severity. Grade IV overall symptom severity was assigned for patients with stage 4 symptom severity in the skin, gut, or liver.
Before the study blind was opened, outcome after treatment was evaluated by two methods, each with a different approach for incorporating the confounding effects of complications other than GVHD. The first method assigned response
Assessment of response.
categories solely according to changes in symptom severity without considering whether abnormalities were caused by GVHD or by other complications. Skin disease was considered improved when there was resolution of rash or decrease in the involved surface area by 2 2 5 percentage points. Progressive skin disease was defined as an increase in the involved surface area by 225 percentage points.
Liver disease was considered improved when there was a decrease in serum bilirubin to <2 mg/dL for patients with baseline values of 2 to 4 mg/dL, a decrease of 2 2 mg/dL for patients with baseline values of 4 to 8 mg/dL, or a 225% decrease in serum bilirubin for patients with baseline values 2 8 mg/dL. Progressive liver disease was defined as an increase of serum bilirubin by 2 2 mg/dL for patients with baseline values <8 mg/dL or 2 2 5 % increase in serum bilirubin for patients with baseline values 2 8 mg/dL. Because an increase or decrease in serum bilirubin can reflect altered renal function, improvement and progression of liver disease were not scored when the direct serum bilirubin and serum creatinine both increased or decreased such that the direct bilirubinmeatinine ratio was changed by <25%.'0.'9 Likewise, liver disease was considered nonevaluable when a "stable" bilirubin was accompanied by an increase or decrease in serum creatinine such that the direct bilirubinxreatinine ratio was changed by >25%. In this situation, an improvement or deterioration in hepatic function could have been masked by an opposite change in renal function.
Gut disease was considered improved when there was resolution of diarrhea or decrease in the 3-day average stool volume by 2500 mL/d with clearing of cramps and bleeding if present. Clearing of cramps and bleeding was considered as evidence of improvement in patients without diarrhea but not in patients with persistent diarrhea. Gut disease was also considered improved when nausea and vomiting resolved in patients who had these symptoms as the only gut abnormalities. Progressive gut disease was defined as an increase in the 3-day average stool volume by 2 5 0 0 mL/d or the development of new cramps or bleeding. Stool volumes were not considered when urinary mixing was present. Factors such as the platelet count and the amount of oral intake and antidiarrhea medications were not taken into account regarding their effect on stool blood and diarrhea volume.
For all organs, assessment of treatment response was made entirely by clinical criteria regardless of biopsy or autopsy findings. Overall complete response (CR) was defined as the absence of symptoms referable to GVHD in all organs. Partial response (PR) was defined as an improvement in at least one organ without deterioration in others.
In the second method for assessment of response, an expert reviewer evaluated results at 4 and 6 weeks after treatment in light of clinically relevant findings other than GVHD. Patients with abnormalities involving the skin, liver or gut at 4 or 6 weeks could nonetheless be assigned as having a CR by this "global assessment" when the abnormalities were restricted to a single organ and were not present in preceding or subsequent evaluations, and a cause other than GVHD could be implicated.
For purposes of toxicity evaluation, renal impairment was defined as a serum creatinine concentration >0.6 mg/dL (53 pmol/L) for patients with baseline values <0.3 mg/dL (27 pmol/ L), an increase to twice the baseline value for patients with serum creatinine concentration of 0.3 to 1 mg/dL (27-88 pmoVL) at the beginning of treatment, or a serum creatinine concentration 2 2 mg/ dL (177 pmoVL) for patients with baseline values > l mg/dL (88 pmoVL). Methods for measurement of the IgG response to immunotoxin have been described previously.2o A positive response was defined as a IO-fold increase above the baseline titer as determined by the enzyme immunoassay.
The prespecified primary endpoint for the study was a comparison of the proportion of patients assigned to each group Toxicity.
Analysis.
For personal use only. on October 27, 2017. by guest www.bloodjournal.org From who were alive with CR at 6 weeks after starting treatment. Secondary endpoints were comparisons of CR at 4 weeks, global assessment of CR at 4 and 6 weeks, CR or PR at 4 and 6 weeks, time to treatment failure defined as secondary treatment for acute GVHD or death from any cause, all cause-mortality, death with infection, clinical extensive chronic GVHD, and renal impairment.
Before comparing treatments, the donor category (HLA-identical relative versus unrelated donor or HLA-mismatched relative), GVHD prophylaxis (methotrexate plus cyclosporine versus other). onset day of GVHD and baseline serum total bilirubin concentration were tested for association with the primary endpoint of complete response at 6 weeks." Only the baseline serum bilirubin concentration showed a significant (inverse) association with this endpoint. Symptom seventy scores were compared at each time point with the Wilcoxon rank sum test and across time points by using rank analysis of covariance'' with adjustment for baseline serum bilirubin level. Response rates were analyzed by logistic regression with adjustment for baseline serum bilirubin level. Survival and times to secondary therapy, treatment failure, and chronic GVHD were analyzed by the log rank test. The frequencies of renal impairment and death with infection were compared with the Chi-square test.
RESULTS
Patients and symptom severity. Demographic characteristics and initial symptom severity were similar among the 129 patients assigned to receive CD5-Plus and the 114 patients assigned to receive placebo (Table 1 and Fig l) . The proportion of evaluable patients relatively free of symptoms (ie, those with grades 0 or 1 symptom severity) in the CD5 group increased from 1% at the beginning of treatment to 17%, 33%, 47%, 55%, 55%, and 48% during the 6 successive weeks after treatment (Fig 1) . The proportion of evaluable patients with grade 0 or 1 symptom severity in the placebo group increased from 0 at the beginning of treatment to lo%, 26%, 30%, 35%, 35%, and 44% during the same time interval. At 3, 4, and 5 weeks after starting treatment, symptom severity was less in the CD5 group than in the placebo group. At 6 weeks, symptom severity was again similar in the two groups. Symptom severity across the entire 6-week study period was lower in the CD5 group than in the placebo group (P = .033).
At 4 weeks, 51 (40%) of the 127 evaluable patients assigned to the CD5 group were alive with a CR compared with 28 (25%) of the 114 in the control group (P = .019) (Fig 2) . Two patients in the CD5 group left Seattle before day 29 and could not be formally evaluated. One of the two had no clinical evidence of acute GVHD at the time of departure. At 6 weeks, 54 (44%) of the 123 evaluable patients assigned to the CD5 group were alive with a CR, compared with 43 (38%) of 114 in the control group (P = .36). Six patients in the CD5 group could not be evaluated at this time, one because of incomplete data, and five because they had already left Seattle. Five of the six had no clinical evidence of acute GVHD at the time of the last complete assessment. The proportions of patients with CR or PR remained relatively constant throughout the period between 2 and 6 weeks after starting treatment ( Fig   Preexisting or new complications affecting the skin, liver, or gut persisted or developed during treatment for GVHD in 74% of patients. Skin complications Response categories.
2).
Global assessment. other than GVHD were identified in 7% of patients, liver complications in 60%, and gastrointestinal complications in 32%, with no significant differences between the CD5 group and the placebo group (data not shown).
After accounting for complications other than GVHD, the proportion of patients with CR at 4 weeks after treatment was higher in the CD5 group than in the placebo group (Fig  3) . A similar trend was evident at 6 weeks. Among the 71 evaluable patients in the CD5 group who did not have CR at 4 weeks, 20 (28%) had CR at 6 weeks. Among 81 patients in the control group who did not have CR at 4 weeks, 18 (22%) had CR at 6 weeks. Ten (18%) of the 57 patients in the CD5 group who had CR at 4 weeks were no longer in CR at 6 weeks. Three had a major recurrence of GVHD, four had a minor recurrence, (transient rash involving <20% of body surface or serum bilirubin transiently increased to 2 to 2.9 mg/dL), two had left Seattle and could not be evaluated, and one patient died on day 42. Four (12%) of the 33 patients in the placebo group who had CR at 4 weeks were no longer in CR at 6 weeks. Two had a major recurrence of GVHD, and two had a minor recurrence. Secondary therapy for acute GVHD was administered to 25% of patients in the CD5 group compared with 33% in the placebo group (P = .16). Treatment failure, defined as administration of secondary therapy for GVHD or death from any cause at any time after enrollment in the study occurred in 66% of patients in the CD5 group compared with 74% in the placebo group (P = .14). Clinical extensive chronic GVHD' developed in 65% of patients in the CD5 group compared with 72% in the placebo group (P = .35). Survival (Fig 4) and causes of death ( Table 2) were similar in the two groups. The incidence of recurrent maligOther endpoints. nancy and product-limit estimates of malignancy-free survival were similar in the two groups (data not shown). Death with infection occurred in 35 (27%) of the 129 patients in the CD5 group, compared with 36 (32%) of the 114 in the control group. Other frequent causes of death were recurrent malignancy, regimen-related toxicity, and acute or chronic GVHD. Administration of study drug was discontinued prematurely in 28 (22%) of the patients assigned to receive CD5-Plus and in 12 (1 1%) of those assigned to receive placebo (P = .019). Allergic reactions manifested as dyspnea, wheezing, hoarseness, or periorbital swelling occurred in four patients after the first dose of CD5-Plus (Table 3) . Allergic reactions were not a cause of treatment discontinuation in the placebo group. Other notable reasons for treatment discontinuation in the CD5 group included For edema and weight gain, and weakness or increased serum CPK levels. One patient treated with CD5-Plus had severe rhabdomyolysis complicated by acute tubular necrosis.
Certain adverse events were notable in the CD5 group. Marked weight gain with severe edema sometimes accompanied by dyspnea occurred in 17% of patients in the CD5 (9) 9 (8) 1 (1) 9 (8) 20 (18) 1 (1) (6) The total numbers of deaths were 73 (57%) among the 129 patients in the CD5 group and 74 (65%) among the 114 patients in the placebo group. Some patients had multiple causes of death. Values in the table are numbers of patients followed in parentheses by the percentage of patients assigned to each group.
Abbreviations: ARDS, Adult respiratory distress syndrome; IP, interstitial pneumonia.
Other causes of death in the CD5 group included multifocal encephalomalacia with vasculopathy, hemolytic uremic syndrome, Epstein-Barr virus-related lymphoproliferative disorder, rhabdomyolysis, myopathy, liver failure (n = 2). bronchiolitis obliterans, congestive heart failure, pancreatitis, and aspiration pneumonia. Other causes of death in the placebo group included hepatic failure (n = 4). myocardial infarction, secondary malignancy, and suicide. The total number of patients who had study drug discontinued prematurely for any reason was 28 (22%) among the 129 in the CD5 group and 12 (11%) among the 114 in the placebo group ( P = ,019).
Some patients had multiple reasons for discontinuation. Values in the table are numbers of patients followed in parentheses by the percentage of patients assigned to each group.
group, compared with 9% in the placebo group. Overall, 10% of patients in the CD5 group had muscle weakness, compared with 5% in the placebo group. One patient in the CD5 group developed an Epstein-Barr virus-related lymphoproliferative syndrome. Human antibody against murine immunoglobulin was detected in 15 (16%) of 93 patients tested in the CD5 group, compared with none of 93 in the placebo group. Renal impairment occurred in 48% of patients in the CD5 group compared with 40% in the placebo group ( P = .25). The incidence and severity of hypoalbuminemia were comparable in the two groups (data not shown). In most cases, side effects other than myopathy were transient and resolved after treatment with immunotoxin was completed.
No significant differences between groups were found in the incidence of infections categorized by organism and site (data not shown). The proportions of patients with absolute neutrophil counts less than 0.5 x lo9 per liter and absolute lymphocyte counts in the blood during successive weeks after treatment were similar in the CD5 group and in the placebo group (data not shown).
DISCUSSION
This report shows that treatment with a CD5-specific immunotoxin is effective in alleviating the symptoms of acute GVHD when added to a conventional regimen of high dose glucocorticoids. Differences between the CD5 group and the placebo group were most apparent between 3 to 5 weeks after starting treatment when there was approximately a 15 percentage point advantage in the proportion of patients with complete resolution of symptoms in the CD5 group. The proportions of patients who had CR or PR were similar in the two groups, indicating that treatment with the immunotoxin did not increase the number of patients with overall improvement.
The optimal timing for assessment of response was not known at the time the study was designed. Results of the For personal use only. on October 27, 2017. by guest www.bloodjournal.org From CDB-SPECIFIC IMMUNOTOXIN FOR GVHD 829 present study underscore the desirability of assessing the entire clinical course after treatment for GVHD because the time course of improvement after treatment for GVHD was different in the CDS group and in the placebo group. The initial rate of improvement was much faster in the CDS group than in the placebo group, but this difference did not persist after the fifth week. No consistent pattern of organ response was found to explain the delayed improvement among patients in the placebo group.
Inflammatory cytokines including interferon-y and tumor necrosis factor-a play a prominent role in causing tissue injury during GVHD." Glucocorticoids inhibit transcription of cytokine genes by interfering with NF-KB and AP-1 promotor mechanisms in activated ~e l l s .~~.~~ Among other actions, glucocorticoids inhibit some effects of interferon-y on macrophage^^^^^^ and prevent the release of tumor necrosis factor when macrophages are activated.'* In addition, glucocorticoids impair the production of interleukin-2 (IL-2) by activated T cellsz9 and inhibit clonal expansion of T cells. 30 Treatment with glucocorticoids might also eliminate activated T cells,31 but symptoms of GVHD recur if glucocorticoid doses are tapered too rapidly," suggesting that not all activated T cells are sensitive to glucocorticoids.
The use of a T-cell-specific immunotoxin for treatment of GVHD was based on the supposition that the T cells responsible for initiating the disease would be eliminated by this treatment. Even though CDS-specific antibodies are rapidly internalized after binding to T cells, most CDS-specific ricin A chain immunoconjugates are not highly cytotoxic in the absence of potentiators such as ammonium chloride or chloroquine which retard delivery of endosomes to lysosomes where proteolytic degradation occurs. 13.32 Previous studies have shown that treatment with CDS-Plus can cause transient reductions in the number of circulating T cells, although the mechanisms for this effect have not been fully el~cidated.'~.'~.'~ Reasons for the absence of lymphopenia induced by treatment with CDS-Plus in the present study remain unclear. Lymphopenia associated with GVHD and glucocorticoid treatment could have obscured effects of the immunotoxin on the number of circulating lymphocytes.
For the most part, the side effects associated with the use of CDS-Plus were manageable. Allergic reactions resolved when treatment was discontinued after the first dose. Weight gain, edema, and dyspnea could be managed in most patients by treatment with diuretics. After the initial case of rhabdomyolysis, serum CPK levels were monitored frequently in all patients, and treatment was discontinued in patients with a pattern of increasing values above the upper limit of normal. Even with this precaution, it is possible that treatment with CDS-Plus might exacerbate myopathy caused by glucocorticoids. The incidence of infection was not increased by treatment with the immunotoxin, consistent with observations that CDS-Plus did not cause either neutropenia or lymphopenia.
Treatment of GVHD with high dose glucocorticoids causes considerable morbidity. Hypertension, hyperglycemia, and infections occur in nearly all patients. In the present study, we made no effort to accelerate the withdrawal of glucocorticoids in patients who had a CR after treatment.
Given that treatment with the immunotoxin accelerated the resolution of symptoms caused by GVHD, it is possible that differences in steroid-induced morbidity between the CDS group and the placebo group would have been apparent if glucocorticoid doses had been tapered more quickly in patients with CR. The question of whether short-term treatment with a T-cell-specific immunotoxin or other similar agents can have a steroid-sparing effect in patients with acute GVHD should be addressed in the design of future studies.
